Lena Schultz

777 citations

18 papers · 617 indexed · h-index 11

Impact in

Toxicology top 5%
- Bioactive Compounds and Antitumor Agents
Biochemistry top 10%
- Eicosanoids and Hypertension Pharmacology

Papers in ⓘ

Toxicology 4
- Bioactive Compounds and Antitumor Agents 4
Pharmacology 9
- Inflammatory mediators and NSAID effects 8

Co-authors: Anton Simeonov (13 shared papers)Ajit Jadhav (13 shared papers)David J. Maloney (11 shared papers)Theodore R. Holman (8 shared papers)Victor Kenyon (5 shared papers)Ganesha Rai (5 shared papers)Masaaki Sakurai (2 shared papers)Netra Joshi (5 shared papers)
Journals: Journal of Medicinal Chemistry (4 papers)Journal of Clinical Oncology (3 papers)PLoS ONE (2 papers)Molecular BioSystems (1 paper)Cancer Immunology Immunotherapy (1 paper)
Partner nations: United States Sweden United Kingdom

In The Last Decade

Lena Schultz

18 papers receiving 606 citations

Peers

Countries citing papers authored by Lena Schultz

Since Specialization

Citations

This map shows the geographic impact of Lena Schultz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lena Schultz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lena Schultz more than expected).

Fields of papers citing papers by Lena Schultz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lena Schultz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lena Schultz. The network helps show where Lena Schultz may publish in the future.

Co-authors

The 25 scholars most cited alongside Lena Schultz, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Lena Schultz Line = papers co-authored together Lena Schultz links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

#	Work
1	A Small Molecule Inhibitor of the BLM Helicase Modulates Chromosome Stability in Human Cells Chemistry & Biology ·Giang Huong Nguyen, Thomas S. Dexheimer, Andrew S. Rosenthal, Wai Kit Chu, Dharmendra Kumar Singh, Georgina Mosedale, Csanád Z. Bachrati, Lena Schultz, Masaaki Sakurai, P. Savitsky, Mika Abu, Peter J. McHugh, Vilhelm A. Bohr, Curtis C. Harris, Ajit Jadhav, O. Gileadi, David J. Maloney, Anton Simeonov, Ian D. Hickson	2013	131
2	Potent and Selective Inhibitors of Human Reticulocyte 12/15-Lipoxygenase as Anti-Stroke Therapies Journal of Medicinal Chemistry ·Ganesha Rai, Netra Joshi, Joo Eun Jung, Yu Liu, Lena Schultz, Adam Yasgar, Steve Perry, Giovanni Diaz, Qiangli Zhang, Victor Kenyon, Ajit Jadhav, Anton Simeonov, Eng H. Lo, Klaus van Leyen, David J. Maloney, Theodore R. Holman	2014	86
3	A miniaturized screen for inhibitors of Jumonji histonedemethylases Molecular BioSystems ·Masaaki Sakurai, Nathan R. Rose, Lena Schultz, Amy Quinn, Ajit Jadhav, Stanley S. Ng, Udo Oppermann, Christopher J. Schofield, Anton Simeonov	2009	76
4	Discovery of Potent and Selective Inhibitors of Human Reticulocyte 15-Lipoxygenase-1 Journal of Medicinal Chemistry ·Ganesha Rai, Victor Kenyon, Ajit Jadhav, Lena Schultz, Michelle Armstrong, J. Brian Jameson, Eric K. Hoobler, William Leister, Anton Simeonov, Theodore R. Holman, David J. Maloney	2010	69
5	Synthesis and Structure–Activity Relationship Studies of 4-((2-Hydroxy-3-methoxybenzyl)amino)benzenesulfonamide Derivatives as Potent and Selective Inhibitors of 12-Lipoxygenase Journal of Medicinal Chemistry ·Diane K. Luci, J. Brian Jameson, Adam Yasgar, Giovanni Diaz, Netra Joshi, Auric Kantz, Kate Markham, Steve Perry, Norine Kuhn, Jennifer Yeung, Edward H. Kerns, Lena Schultz, Michael Holinstat, Jerry L. Nadler, David Taylor, Ajit Jadhav, Anton Simeonov, Theodore R. Holman, David J. Maloney	2014	65
6	Discovery of Potent and Selective Inhibitors of Human Platelet-Type 12- Lipoxygenase Journal of Medicinal Chemistry ·Victor Kenyon, Ganesha Rai, Ajit Jadhav, Lena Schultz, Michelle Armstrong, J. Brian Jameson, Steve Perry, Netra Joshi, James M. Bougie, William Leister, David Taylor, Jerry L. Nadler, Michael Holinstat, Anton Simeonov, David J. Maloney, Theodore R. Holman	2011	55
7	Inhibition of thioredoxin reductase 1 by porphyrins and other small molecules identified by a high-throughput screening assay Free Radical Biology and Medicine ·Stefanie Prast‐Nielsen, Thomas S. Dexheimer, Lena Schultz, William C. Stafford, Qing Cheng, Jianqiang Xu, Ajit Jadhav, Elias S.J. Arnér, Anton Simeonov	2011	29
8	High-Affinity Inhibitors of Human NAD+-Dependent 15-Hydroxyprostaglandin Dehydrogenase: Mechanisms of Inhibition and Structure-Activity Relationships PLoS ONE ·F. Niesen, Lena Schultz, Ajit Jadhav, C. Bhatia, Kunde Guo, David J. Maloney, Ewa S. Pilka, Minghua Wang, Udo Oppermann, Tom D. Heightman, Anton Simeonov	2010	29
9	A High Throughput Screen Identifies Potent and Selective Inhibitors to Human Epithelial 15-Lipoxygenase-2 PLoS ONE ·J. Brian Jameson, Auric Kantz, Lena Schultz, Chakrapani Kalyanaraman, Matthew P. Jacobson, David J. Maloney, Ajit Jadhav, Anton Simeonov, Theodore R. Holman	2014	21
10	Discovery of ML355, a Potent and Selective Inhibitor of Human 12-Lipoxygenase Diane K. Luci, J. Brian Jameson, Adam Yasgar, Giovanni Diaz, Netra Joshi, Auric Kantz, Kate Markham, Steve Perry, Norine Kuhn, Jennifer Yeung, Lena Schultz, Michael Holinstat, Jerry L. Nadler, David Taylor, Ajit Jadhav, Anton Simeonov, Theodore R. Holman, David J. Maloney	2014	17
11	Discovery of ML351, a Potent and Selective Inhibitor of Human 15-Lipoxygenase-1 Europe PMC (PubMed Central) ·Ganesha Rai, Netra Joshi, Steve Perry, Adam Yasgar, Lena Schultz, Jog Eun Jung, Yu Liu, Yasukazu Terasaki, Giovanni Diaz, Victor Kenyon, Ajit Jadhav, Anton Simeonov, Klaus van Leyen, Theodore R. Holman, David J. Maloney	2014	12
12	The role of the development of hypertension or proteinuria in predicting outcome with the use of bevacizumab for patients with glioblastoma multiforme (GBM). Journal of Clinical Oncology ·Chaitali Nangia, D. Wang, Lisa Scarpace, Lena Schultz, Ammar Khanshour, Tom Mikkelsen	2011	8
13	A first-in-human phase I study in patients with advanced and/or refractory solid malignancies to evaluate the safety of ATOR-1015, a CTLA-4 x OX40 bispecific antibody. Journal of Clinical Oncology ·Jeffrey Yachnin, Gustav Ullenhag, Ana Paula Carneiro, Dorte Nielsen, Kristoffer Staal Rohrberg, Anne Månsson Kvarnhammar, Lena Schultz, Erika Bågeman, Camilla Wennersten, Charlotte Russell	2020	7
14	ATOR-1017 (evunzekibart), an Fc-gamma receptor conditional 4-1BB agonist designed for optimal safety and efficacy, activates exhausted T cells in combination with anti-PD-1 Cancer Immunology Immunotherapy ·Karin Enell Smith, Sara Fritzell, Anneli Nilsson, Karin Barchan, Anna Rosén, Lena Schultz, Laura A. Varas, Anna Säll, Nadia Rose, M. Håkansson, Laura von Schantz, Peter Ellmark	2023	6
15	Potent and selective inhibitors of NAD+-dependent 15-hydroxyprostaglandin dehydrogenase (HPGD) Ajit Jadhav, F. Niesen, Lena Schultz, Udo Oppermann, David J. Maloney, Anton Simeonov	2011	2
16	Selective Small Molecule Inhibitors of 12-Human Lipoxygenase (12-hLO) Ganesha Rai, Ajit Jadhav, Lena Schultz, Victor Kenyon, William Leister, Anton Simeonov, Theodore R. Holman, David J. Maloney	2011	2
17	First-in-human, multicenter, open-label, phase I study of ATOR-1017 (evunzekibart), a 4-1BB antibody, in patients with advanced solid malignancies Journal for ImmunoTherapy of Cancer ·Ana Paula Carneiro, Amanda Hahn, Peter Ellmark, Karin Enell Smith, Lena Schultz, Sumeet Ambarkhane, Jeffrey Yachnin, Gustav Ullenhag	2025	1
18	Initial findings from a first-in-human, multicenter, open-label study of ATOR-1017, a 4-1BB antibody, in patients with advanced solid malignancies. Journal of Clinical Oncology ·Gustav Ullenhag, Ana Paula Carneiro, Karin Enell Smith, Lena Schultz, Sumeet Ambarkhane, Tova Landstrom, Jeffrey Yachnin	2022	1

About Lena Schultz

Lena Schultz is a scholar working on Toxicology, Pharmacology, Biochemistry, Genetics and Oncology, having authored 18 papers that have together received 617 indexed citations. Recurring topics across this work include Inflammatory mediators and NSAID effects (8 papers), Bioactive Compounds and Antitumor Agents (4 papers), Estrogen and related hormone effects (4 papers), Cancer Immunotherapy and Biomarkers (3 papers), Eicosanoids and Hypertension Pharmacology (3 papers), CAR-T cell therapy research (2 papers), Receptor Mechanisms and Signaling (2 papers) and Immune Cell Function and Interaction (2 papers). The work is most often cited by research in Toxicology (48 citations), Biochemistry (80 citations), Pharmacology (99 citations), Molecular Biology (363 citations) and Organic Chemistry (100 citations). Lena Schultz has collaborated with scholars based in United States, Sweden and United Kingdom. Frequent co-authors include Anton Simeonov, Ajit Jadhav, David J. Maloney, Theodore R. Holman, Victor Kenyon, Ganesha Rai, Masaaki Sakurai, Netra Joshi, Steve Perry and Udo Oppermann. Their work appears in journals such as Journal of Medicinal Chemistry, Journal of Clinical Oncology, PLoS ONE, Molecular BioSystems and Cancer Immunology Immunotherapy.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact